Graft-Versus-Host Disease (GVHD)
What is Graft-Versus-Host Disease (GVHD)?
Graft-Versus-Host Disease is a condition that can happen after you receive a stem cell or bone marrow transplant. The donor cells, which are meant to replace your immune system, sometimes recognize your body tissues as foreign. These new immune cells then attack your organs and tissues.
GVHD can appear soon after transplant or months to years later. Acute GVHD typically develops within the first 100 days after transplant. Chronic GVHD appears later and can last much longer. Both types can affect multiple organs including your skin, liver, digestive tract, and eyes.
This condition ranges from mild to severe and life-threatening. Early detection through blood testing and symptom monitoring helps doctors adjust treatment quickly. Understanding how your body responds to transplant allows your medical team to balance fighting disease while protecting healthy tissue.
Symptoms
- Skin rash, redness, or discolored patches that may peel or blister
- Persistent diarrhea or abdominal cramping
- Nausea, vomiting, or loss of appetite
- Yellowing of the skin or eyes, also called jaundice
- Dry, irritated, or painful eyes
- Dry mouth or mouth sores
- Liver inflammation causing elevated liver enzymes
- Shortness of breath or persistent cough
- Joint stiffness or muscle weakness
- Fatigue and overall feeling unwell
Some people experience mild symptoms that develop gradually over time. Others may have severe symptoms that appear suddenly and require immediate medical attention.
Concerned about Graft-Versus-Host Disease (GVHD)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
GVHD occurs when donor immune cells attack your body after a stem cell or bone marrow transplant. The donor cells see your tissues as foreign invaders. This immune response targets organs throughout your body, especially the skin, liver, and digestive system. The closer the tissue match between donor and recipient, the lower the risk.
Risk factors include receiving cells from an unrelated donor or mismatched family member. Older age at transplant, female donor to male recipient, and previous infections also increase risk. The type of transplant and conditioning treatment you receive before transplant affect your chances. About 30 to 50 percent of people who receive transplants from matched siblings develop some form of GVHD.
How it's diagnosed
Doctors diagnose GVHD through a combination of physical examination, symptom review, and laboratory tests. Blood tests play a critical role in detecting liver involvement. Alanine Aminotransferase (ALT) levels rise when GVHD affects your liver, indicating immune-mediated damage to bile ducts and liver cells. Regular ALT monitoring helps distinguish GVHD from other post-transplant issues like infections or medication side effects.
Rite Aid offers ALT testing as part of our preventive health panel. Regular monitoring after transplant helps your medical team catch liver GVHD early and track how well immunosuppressive treatments are working. Your doctor may also perform skin biopsies, endoscopy, or additional liver function tests to confirm the diagnosis and determine severity.
Treatment options
- Corticosteroids like prednisone or methylprednisolone to reduce immune system activity
- Immunosuppressive medications such as tacrolimus, cyclosporine, or sirolimus
- Targeted therapies including ruxolitinib for steroid-resistant cases
- Phototherapy or topical treatments for skin symptoms
- Careful skin care with gentle moisturizers and sun protection
- Nutrition support including easy-to-digest foods if digestive tract is affected
- Eye drops and lubricants for dry eyes
- Physical therapy to maintain mobility and strength
- Infection prevention measures since medications weaken immune defenses
- Regular monitoring with blood tests to track treatment response
Concerned about Graft-Versus-Host Disease (GVHD)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Acute GVHD typically occurs within the first 100 days after transplant and mainly affects the skin, liver, and digestive tract. Chronic GVHD develops later, often after day 100, and can affect more organs including eyes, mouth, lungs, and joints. Chronic GVHD may persist for months or years and often requires longer treatment.
Doctors take steps to reduce GVHD risk but cannot prevent it entirely. Preventive strategies include giving immunosuppressive medications immediately after transplant, carefully matching donors, and sometimes removing certain immune cells from the donor graft. Close tissue matching between donor and recipient lowers risk significantly.
ALT is a liver enzyme that rises when GVHD damages liver cells and bile ducts. Regular ALT monitoring helps doctors detect liver GVHD early, before symptoms become severe. It also helps distinguish GVHD from other causes of liver problems like infections or medication toxicity. Tracking ALT levels over time shows whether treatments are working.
GVHD severity varies widely from person to person. Mild cases may cause minor skin rash or digestive upset that responds well to treatment. Severe cases can be life-threatening and affect multiple organs at once. Early detection and prompt treatment improve outcomes significantly.
Blood test frequency depends on your individual situation and time since transplant. Most patients need testing weekly or biweekly in the first few months, then monthly as recovery progresses. Your transplant team will create a monitoring schedule based on your risk factors and symptoms. Regular testing catches problems early when they are easier to treat.
Nutrition plays an important supporting role in GVHD management. If your digestive tract is affected, you may need easy-to-digest foods, smaller frequent meals, and avoidance of spicy or acidic items. Good nutrition supports healing and helps your body tolerate medications. A dietitian familiar with transplant care can provide personalized guidance.
Persistently high ALT levels suggest ongoing liver inflammation from GVHD or another cause. Your doctor may adjust immunosuppressive medications, add new treatments, or perform additional tests like liver biopsy. Close monitoring continues until ALT levels return toward normal range, indicating the liver inflammation is resolving.
Yes, GVHD can flare up again even after responding well to treatment. This happens most often when immunosuppressive medications are reduced or stopped. Regular monitoring with blood tests and symptom tracking helps catch flares early. Your medical team will taper medications slowly while watching closely for signs of recurrence.
Long-term immunosuppressive treatment can increase infection risk and may affect bone density, blood sugar, and blood pressure. Regular monitoring helps catch these side effects early. Many people eventually taper off medications completely, while others need low-dose maintenance therapy. Your transplant team balances controlling GVHD with minimizing medication side effects.
Contact your transplant team immediately if you develop new rash, yellowing skin or eyes, persistent diarrhea, or abdominal pain. Report any changes in your condition, even if they seem minor. Early intervention prevents mild GVHD from becoming severe. Keep all scheduled appointments and blood test monitoring even when you feel well.